# Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

> **NCT01852110** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 240 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK-7622
- **DRUG:** Placebo
- **DRUG:** AChEI

## Key facts

- **NCT ID:** NCT01852110
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10-22
- **Primary completion:** 2016-04-11
- **Final completion:** 2016-04-11
- **Target enrollment:** 240 (ACTUAL)
- **Why stopped:** Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852110, "Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01852110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*